Semaglutide and AOD 9604: Is There Synergistic Potential?


In the following article, we will discuss the alleged synergistic potential that the compounds Semaglutide and AOD 9604 exhibit. Both of these chemicals are the subject of great interest and enthusiasm, and researchers are keen to investigate the potential each may have within the realm of obesity and diabetes research. Studies conducted up to this point have suggested that the combination of these two substances may induce weight loss and maintained over a period of some duration.

Novo Nordisk developed Semaglutide in 2012 as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It has been speculated that this substance may potentially enhance insulin secretion and retard gastric emptying, leading to a greater potential regulation of blood sugar levels. Research findings in Semaglutide appeared to have induce weight loss in test models at approximately 5.5% of their overall weight after 68 weeks, while control models were reported to lose an average of 1.6% of body weight in comparison.

AOD 9604 is a peptide produced in the 1990s by Commonwealth Serum Laboratories, an organization based in Australia. Findings imply that this peptide, which is generated from growth hormone (hGH), may increase lipolysis (the process of burning fat) and block lipogenesis (the process of forming fat cells). AOD 9604, on the other hand, has so far not been found to induce insulin resistance in the manner of hGH.

Semaglutide, AOD 9604, and Weight Research

Professionals purport that Semaglutide may work by delaying the emptying of the stomach and boosting insulin production; as a result, it may assist in regulating blood sugar levels. When there is good control over the sugar levels in the blood, an organism has a lower propensity to store extra calories as fat. Meanwhile, it is implied that AOD 9604 may encourage lipolysis, which is the breakdown of fat, while inhibiting lipogenesis, which is fat production. Therefore, combining these two substances may synergize to potentially induce weight loss and metabolism increase.

In one research study published in 2008, rats were separated into four different groups:

  • A control group receiving saline solution
  • An experimental group receiving AOD 9604 peptide
  • An experimental group receiving Semaglutide peptide
  • An experimental group receiving a combination of AOD 9604 and Semaglutide compounds

The findings suggested that the group of rats presented with both chemicals exhibited a rate of weight loss that was noticeably greater than any other group. These findings imply that combining these two compounds may significantly impact weight.

Another research study published in 2012, investigated the potential effects of this blend on models of obesity. During this research project, 40 obese models were given either a placebo compound or AOD 9604/Semaglutide weekly for 12 weeks. As suggested by the findings, models presented with the experimental compounds weighed in to a reported average of 3% loss in weight. In comparison, those given a placebo exhibited a reported average of 0.5% loss  in weight. In addition, research models in the intervention group reportedly exhibited considerable changes in their Insulin Sensitivity Index (ISI), which suggests that this blend may postentially assist in enhancing insulin sensitivity.

Concluding remarks:

The research results on animal models suggest that Semaglutide and AOD 9604 may be promising for ongoing obesity-research. The findings of these studies purported that presenting Semaglutide in combination with AOD 9604 may result in weight reduction in obese models.

Buy Semaglutide (GLP-1) only if you are a licensed professional or academic looking for compounds for experimental studies.


[i] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

[ii] Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.

[iii] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27. PMID: 34706925; PMCID: PMC8717485.

[iv] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. PMID: 36216945; PMCID: PMC9556320.

[v] Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004 Apr;5(4):436-40. PMID: 15134286.

[vi] Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.